Skip to main content
Premium Trial:

Request an Annual Quote

Purely Proteins Licenses Database to Cytomyx

NEW YORK, Dec. 12-The British company Purely Proteins has licensed its gene and protein database to Cytomyx, the company said today.

 

Cytomyx obtained a license to use the TargetBASE Plus database for data regarding G-protein coupled receptors.

 

Purely Proteins' databases include both public and proprietary information about proteins, targets and ligands. Its TargetBASE database includes nucleotide, EST, and protein information organized in gene families. The company is based in Cambridge, UK.

 

Cytomyx develops gene- and protein-based tools for pharmaceutical research. It is also based in Cambridge.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.